Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Bill Wexler's Profits of DOOM -- Ignore unavailable to you. Want to Upgrade?

To: Bill Wexler who wrote (641)	4/9/1998 4:16:00 PM
From: Hank	Respond to of 4634

Congratulations Bill!! I declare you the winner of your bet with "Dr" Dewave the Fecalogist. I've been waiting to catch him posting again in order to confirm that he read my challenge. It appears he has. That's not all he has done. He has changed his profile to reflect the fact that he is neither a PhD nor an MD nor a Medical Director. Good work.

To: Bill Wexler who wrote (641)	4/9/1998 6:26:00 PM
From: Biojunkie	Read Replies (2) \| Respond to of 4634

Bill, I've researched the science of this company and others that are targeting Cellular factors to inhibit HIV replication. This month Dr. Gallo is one of the key note speakers at a conference in Italy titled "Cellular factors, targets for HIV replication'. It's a fact that the HIV virus has mutated around all current therapies that target the viral structure. It would be a shame if "SHORTS" like you are allowed to misrepresent this new approch and companies technology. HIV patients need new theraputic treatments and I applaude this companies guts to bring this new approach to the clinical trial process.